Abstract
The indicated Bayer patents disclose some analogues of the known activator of soluble guanylate cyclase (sGC) and phosphodiesterase inhibitor 3-(5-hydroxymethyl-2-furyl)-1-benzylindazole (YC-1). The compounds are shown to be exceptionally potent in in vitro cell based assays and in some in vivo systems such as blood pressure lowering in spontaneously hypertensive rats. This potent activity seems to differentiate these compounds from other reported activators.